/

Sociétés

Ma

Non vérifié

Massive Bio

Ce que nous écrivons

IndustrieMédecine - DiversMultimédiaOncologieSanté

23 communiqués de presse

Voir tous les communiqués de presse

03/06/2026

Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients

Source

Émetteur

1.00

0

30/05/2026

Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026

Source

Émetteur

1.00

0

29/05/2026

Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials

Source

Émetteur

1.00

0

28/05/2026

Massive Bio to Unveil Reticulum Nexus™ as the AI Operating System for Oncology Access at ASCO 2026

Source

Émetteur

1.00

0

21/05/2026

Massive Bio and BeeKeeperAI Deploy Federated Confidential Computing to Expand Oncology Trial Access Across Atlanta’s Underserved Communities

Source

Émetteur

1.00

0

14/05/2026

Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials

Source

Émetteur

1.00

0

28/04/2026

Massive Bio Expands Global Access to Clinical Trials Through AI-Powered Parameterization and Pre-Screening with OpenAI

Source

Émetteur

1.00

0

09/04/2026

Massive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients

Source

Émetteur

1.00

0

19/03/2026

Massive Bio Launches NexusPulse™, the Real-Time AI Signal Engine for Oncology Markets

Source

Émetteur

1.00

0

02/02/2026

Massive Bio Launches TrialRelay™ at SCOPE 2026: An Operating System to End "Referral Black Holes" in Oncology

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0